A Multicenter, Phase I/II dose escalation study to evaluate the toxicity of once weekly Panobinostat combined with Bortezomib, Cyclophosphamide and Dexamethasone in Treatment Naive Myeloma patients

Trial Profile

A Multicenter, Phase I/II dose escalation study to evaluate the toxicity of once weekly Panobinostat combined with Bortezomib, Cyclophosphamide and Dexamethasone in Treatment Naive Myeloma patients

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Panobinostat (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms PANACHE
  • Most Recent Events

    • 24 Jul 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 06 Dec 2013 Planned initiation date changed from 1 May 2013 to 1 Feb 2014 as reported by Australian New Zealand Clinical Trials Registry record.
    • 08 Apr 2013 Planned initiation date changed from 7 Jan 2013 to 1 May 2013 as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top